Stevanato Group, an Italy-based producer of glass primary packaging, and Haselmeier, a Switzerland and Germany-based developer and manufacturer of self-injection devices, have entered an exclusive agreement to license the Axis-D pen-injector technology and intellectual property (IP) in the Therapeutic Area of Diabetes Care.   The Axis-D pen-injector was designed and developed by Haselmeier together with its partners; a version of this pen-injector is currently on the market, having been launch...